The FDA has approved labeling changes for erectile dysfunction drugs in the class that includes tadalafil (Cialis), vardenafil (Levitra), and sildenafil citrate (Viagra), to display more prominently the potential risk of sudden hearing loss and to guide consumers on what to do if they experience sudden problems with their hearing.
The FDA has approved labeling changes for erectile dysfunction drugs in the class that includes tadalafil (Cialis), vardenafil (Levitra), and sildenafil citrate (Viagra), to display more prominently the potential risk of sudden hearing loss and to guide consumers on what to do if they experience sudden problems with their hearing.
The FDA asked manufacturers of phosphodiesterase type-5 inhibitors to revise product labeling after a small number of patients taking the drugs reported sudden hearing loss, sometimes accompanied by ringing in the ears and dizziness.
“Because some level of hearing loss is usually associated with the aging process, patients on these drugs may not think to talk to their doctor about it,” said Janet Woodcock, MD, of the FDA’s Center for Drug Evaluation and Research.
Patients who are taking any of the three drugs and experience sudden hearing loss are being instructed to immediately stop taking the drug and seek prompt medical attention. Although no causal relationship has been demonstrated, the strong relationship between the use of these drugs and sudden hearing loss in these cases warrants revisions to the product labeling for this drug class, the FDA said.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.